The Patent Finder

Targeting Rare Human PCSK9 Variants for Cholesterol Treatment (2013)

Kymab Limited

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 61/916,862, filed Dec 17, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,883,157Targeting Rare Human PCSK9 Variants for Cholesterol Treatment
In force
 · High confidence
Kymab LimitedIn force
High confidence
US 8,951,523Targeting Rare Human PCSK9 Variants for Cholesterol Treatment
In force
 · High confidence
Kymab LimitedIn force
High confidence
US 9,040,052Precision Medicine By Targeting Rare Human PCSK9 Variants for Cholesterol Treatment
In force
 · High confidence
Kymab LimitedIn force
High confidence
US 10,611,849Precision Medicine by Targeting Rare Human PCSK9 Variants for Cholesterol Treatment
In force
 · High confidence
Kymab LimitedIn force
High confidence
US 10,618,971Targeting Rare Human PCSK9 Variants for Cholesterol Treatment
In force
 · High confidence
Kymab LimitedIn force
High confidence
US 11,434,305Precision Medicine by Targeting Rare Human PCSK9 Variants for Cholesterol Treatment
In force
 · High confidence
Kymab LimitedIn force
High confidence
Application 17/875,720Human Targets
Abandoned
Abandoned Oct 31, 2025
Kymab LimitedAbandonedAbandoned Oct 31, 2025
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Kymab Limited.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited